Table 3. ELISpot response rates to any HIV peptide by study visit and study group.
Study group | ||||||||
Total | DNA+ rAd5 IM | DNA+ rAd5 ID | DNA+ rAd5 SC | |||||
+/n | (%) | +/n | (%) | +/n | (%) | +/n | (%) | |
Baseline | 2/58 | (3.4) | 1/19 | (5.3) | 0/18 | (0.0) | 1/20 | (5.0) |
2 weeks post DNA series | 24/57 | (42.1) | 8/18 | (44.4) | 10/20 | (50.0) | 6/19 | (31.6) |
4 weeks post rAd5 boost | 21/51 | (41.2) | 7/15 | (46.7) | 6/17 | (35.3) | 8/18 | (44.4) |